[go: up one dir, main page]

NO20041520L - Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin. - Google Patents

Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin.

Info

Publication number
NO20041520L
NO20041520L NO20041520A NO20041520A NO20041520L NO 20041520 L NO20041520 L NO 20041520L NO 20041520 A NO20041520 A NO 20041520A NO 20041520 A NO20041520 A NO 20041520A NO 20041520 L NO20041520 L NO 20041520L
Authority
NO
Norway
Prior art keywords
tetrahydroisoquinol
methanesulfonamido
quinazoline
dimethoxy
pyridyl
Prior art date
Application number
NO20041520A
Other languages
English (en)
Norwegian (no)
Inventor
Ross James Macrae
Michael John Humphrey
Janet Sarah Smith
John Douglas David
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20041520L publication Critical patent/NO20041520L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20041520A 2001-10-11 2004-04-05 Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin. NO20041520L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124455.7A GB0124455D0 (en) 2001-10-11 2001-10-11 Pharmaceutical formulations
PCT/IB2002/004040 WO2003032956A1 (en) 2001-10-11 2002-09-30 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline

Publications (1)

Publication Number Publication Date
NO20041520L true NO20041520L (no) 2004-04-05

Family

ID=9923660

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041520A NO20041520L (no) 2001-10-11 2004-04-05 Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin.

Country Status (32)

Country Link
EP (1) EP1434570B8 (es)
JP (1) JP4131471B2 (es)
KR (1) KR20050032510A (es)
CN (1) CN1568180A (es)
AP (1) AP2004003001A0 (es)
AR (1) AR036782A1 (es)
AT (1) ATE303135T1 (es)
BR (1) BR0213196A (es)
CA (1) CA2461168A1 (es)
CO (1) CO5560534A2 (es)
DE (1) DE60205925T2 (es)
DK (1) DK1434570T3 (es)
DO (1) DOP2002000464A (es)
EA (1) EA006168B1 (es)
ES (1) ES2246017T3 (es)
GB (1) GB0124455D0 (es)
GT (1) GT200200184A (es)
HR (1) HRP20040261A2 (es)
HU (1) HUP0600064A3 (es)
IL (1) IL160969A0 (es)
IS (1) IS7179A (es)
MA (1) MA27075A1 (es)
MX (1) MXPA04003293A (es)
NO (1) NO20041520L (es)
OA (1) OA12709A (es)
PA (1) PA8556001A1 (es)
PE (1) PE20030551A1 (es)
PL (1) PL369666A1 (es)
SV (1) SV2004001279A (es)
UY (1) UY27477A1 (es)
WO (1) WO2003032956A1 (es)
ZA (1) ZA200401976B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
HK1218080A1 (zh) 2013-03-14 2017-02-03 Amgen Inc. 雜環化合物和其用途
KR101943592B1 (ko) 2017-08-31 2019-01-30 조현우 데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE104826T1 (de) * 1990-07-02 1994-05-15 Bend Res Inc Asymmetrische mikroporoese kuegelchen fuer regulierbare freigabe.
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
IL150634A0 (en) * 2000-03-03 2003-02-12 Pfizer 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs

Also Published As

Publication number Publication date
HUP0600064A3 (en) 2007-02-28
EP1434570B1 (en) 2005-08-31
ES2246017T3 (es) 2006-02-01
SV2004001279A (es) 2004-02-19
JP4131471B2 (ja) 2008-08-13
GB0124455D0 (en) 2001-12-05
CA2461168A1 (en) 2003-04-24
BR0213196A (pt) 2004-08-31
DK1434570T3 (da) 2005-11-07
EP1434570A1 (en) 2004-07-07
AP2004003001A0 (en) 2004-03-31
UY27477A1 (es) 2003-05-30
HRP20040261A2 (en) 2004-08-31
JP2005507909A (ja) 2005-03-24
IS7179A (is) 2004-03-11
PL369666A1 (en) 2005-05-02
MXPA04003293A (es) 2004-07-23
AR036782A1 (es) 2004-10-06
MA27075A1 (fr) 2004-12-20
CO5560534A2 (es) 2005-09-30
EA006168B1 (ru) 2005-10-27
EA200400431A1 (ru) 2004-08-26
EP1434570B8 (en) 2005-10-26
KR20050032510A (ko) 2005-04-07
DE60205925T2 (de) 2006-06-08
ATE303135T1 (de) 2005-09-15
CN1568180A (zh) 2005-01-19
DOP2002000464A (es) 2003-04-15
PE20030551A1 (es) 2003-06-26
HUP0600064A2 (en) 2006-06-28
IL160969A0 (en) 2004-08-31
PA8556001A1 (es) 2003-07-28
DE60205925D1 (de) 2005-10-06
WO2003032956A1 (en) 2003-04-24
ZA200401976B (en) 2004-07-12
OA12709A (en) 2006-06-26
GT200200184A (es) 2003-05-23

Similar Documents

Publication Publication Date Title
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DK1448235T3 (da) Orale, farmaceutiske sammensætninger af 5,8,14-triaza-tetracyclo[10.3.1.0(2,11).0(4.9)]-hexadeca-2(11),3,5,7,9-pentaen med kontrolleret frigivelse
EE200200201A (et) Trüosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine.
ATE355278T1 (de) Isochinolinon derivate als parp inhibitoren
NO20052497D0 (no) Fremgangsmater for selektiv inhibering av Janus tyrosinkinase 3 (JAK3).
DK1341774T3 (da) Kondenserede heteroaromatiske glucokinase-aktivatorer
IS6524A (is) 5-alkýlpyrídó(3-3-D)pyrimídín týrósín kínasa tálmar
DZ3425A1 (fr) Derives de quinolinone en tant qu'inhibiteurs kinases de tyrosine
DK1377556T3 (da) Pyrazolderivater til behandling af HIV
ATE320256T1 (de) Succinate des 5,8,14-triazatetracyclo(10.3.1.0 2, 11 .0 4,9 )-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
IS6925A (is) Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns
ATE264328T1 (de) Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
IS6956A (is) Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
NO20035540D0 (no) Eksoterme preparater til behandling av ektoparasitter
DE60202782D1 (de) Verbindungen, welche die freisetzung von cytokinen inhibieren
HRP20030695B1 (hr) Postupak za pripravljanje imidazolnih spojeva
HUP0300006A3 (en) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs, process for their preparation and pharmaceutical compositions containing them
NO20041520L (no) Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin.
SE0001373D0 (sv) NPY Y1 receptor agonists and antagonists
NO20040549L (no) Komplettering av laterale bronnboringer.
DK1345605T3 (da) Varmformet lægemiddelsammensætning til styret afgivelse af perindopril
HK1062439A (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
AU2002256260A1 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas